X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare ALEMBIC PHARMA with ALEMBIC LTD - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALEMBIC PHARMA vs ALEMBIC LTD - Comparison Results

ALEMBIC LTD 
   Change

Alembic Limited, in its 99 years of existence, has evolved from being a tincture manufacturer to one of the prominent indigenous pharma companies in India. It is among the top players in the macrolides (anti-infective) and anti-microbials (animal hea... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALEMBIC PHARMA ALEMBIC LTD ALEMBIC PHARMA/
ALEMBIC LTD
 
P/E (TTM) x 27.2 52.3 52.0% View Chart
P/BV x 5.5 2.2 251.3% View Chart
Dividend Yield % 0.6 0.5 132.5%  

Financials

 ALEMBIC PHARMA   ALEMBIC LTD
EQUITY SHARE DATA
    ALEMBIC PHARMA
Mar-18
ALEMBIC LTD
Mar-18
ALEMBIC PHARMA/
ALEMBIC LTD
5-Yr Chart
Click to enlarge
High Rs64572 896.0%   
Low Rs47034 1,385.8%   
Sales per share (Unadj.) Rs166.14.7 3,533.0%  
Earnings per share (Unadj.) Rs21.96.1 358.8%  
Cash flow per share (Unadj.) Rs27.56.2 440.2%  
Dividends per share (Unadj.) Rs4.000.20 2,000.0%  
Dividend yield (eoy) %0.70.4 190.0%  
Book value per share (Unadj.) Rs117.840.7 289.6%  
Shares outstanding (eoy) m188.52267.03 70.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.411.3 29.8%   
Avg P/E ratio x25.58.7 293.4%  
P/CF ratio (eoy) x20.38.5 239.2%  
Price / Book Value ratio x4.71.3 363.5%  
Dividend payout %18.33.3 557.5%   
Avg Mkt Cap Rs m105,09014,139 743.3%   
No. of employees `000NANA-   
Total wages/salary Rs m6,228207 3,002.9%   
Avg. sales/employee Rs ThNMNM-  
Avg. wages/employee Rs ThNMNM-  
Avg. net profit/employee Rs ThNMNM-  
INCOME DATA
Net Sales Rs m31,3081,255 2,494.3%  
Other income Rs m70370 19.0%   
Total revenues Rs m31,3781,625 1,930.5%   
Gross profit Rs m6,431111 5,788.4%  
Depreciation Rs m1,05538 2,789.9%   
Interest Rs m342 2,000.0%   
Profit before tax Rs m5,413442 1,225.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m-811,212 -6.7%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,20424 5,025.1%   
Profit after tax Rs m4,1281,630 253.3%  
Gross profit margin %20.58.9 232.1%  
Effective tax rate %22.25.4 410.2%   
Net profit margin %13.2129.8 10.2%  
BALANCE SHEET DATA
Current assets Rs m18,2471,867 977.3%   
Current liabilities Rs m11,235591 1,900.4%   
Net working cap to sales %22.4101.6 22.0%  
Current ratio x1.63.2 51.4%  
Inventory Days Days8694 90.8%  
Debtors Days Days6174 83.4%  
Net fixed assets Rs m20,0351,791 1,118.7%   
Share capital Rs m377534 70.6%   
"Free" reserves Rs m21,82410,324 211.4%   
Net worth Rs m22,20110,858 204.5%   
Long term debt Rs m5,00041 12,135.9%   
Total assets Rs m39,41111,591 340.0%  
Interest coverage x160.2260.9 61.4%   
Debt to equity ratio x0.20 5,935.1%  
Sales to assets ratio x0.80.1 733.6%   
Return on assets %10.614.1 75.0%  
Return on equity %18.615.0 123.9%  
Return on capital %19.715.2 129.9%  
Exports to sales %46.41.5 3,003.7%   
Imports to sales %10.521.0 50.1%   
Exports (fob) Rs m14,53519 74,921.6%   
Imports (cif) Rs m3,288263 1,248.7%   
Fx inflow Rs m14,72219 75,884.5%   
Fx outflow Rs m7,026264 2,663.1%   
Net fx Rs m7,696-244 -3,148.6%   
CASH FLOW
From Operations Rs m3,124236 1,324.9%  
From Investments Rs m-8,844-224 3,948.1%  
From Financial Activity Rs m5,026-27 -18,895.9%  
Net Cashflow Rs m-693-15 4,684.5%  

Share Holding

Indian Promoters % 74.1 64.0 115.8%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 2.9 0.2 1,450.0%  
FIIs % 9.1 9.7 93.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 13.9 26.1 53.3%  
Shareholders   49,328 54,701 90.2%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALEMBIC PHARMA With:   CIPLA  PFIZER  ALKEM LABORATORIES  SHASUN PHARMA  SANOFI INDIA  

Compare ALEMBIC PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices End Positively, Aavas Financiers IPO, and Top Stocks in Action Today(Pre-Open)

Share markets in India ended on a positive note yesterday with gains largely seen in the banking sector and healthcare sector.

Related Views on News

ALEMBIC LTD Announces Quarterly Results (1QFY19); Net Profit Up 106.9% (Quarterly Result Update)

Aug 10, 2018 | Updated on Aug 10, 2018

For the quarter ended June 2018, ALEMBIC LTD has posted a net profit of Rs 69 m (up 106.9% YoY). Sales on the other hand came in at Rs 445 m (up 50.4% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.

ALEMBIC PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 42.6% (Quarterly Result Update)

Jul 30, 2018 | Updated on Jul 30, 2018

For the quarter ended June 2018, ALEMBIC PHARMA has posted a net profit of Rs 904 m (up 42.6% YoY). Sales on the other hand came in at Rs 9 bn (up 33.1% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

My First Pharma Stock Recommendation!(The 5 Minute Wrapup)

Sep 21, 2018

This company has not only created a niche in the pharma space, it has done so profitably.

Oh Yes! This is the Best Trading Opportunity in Two Decades(Profit Hunter)

Sep 21, 2018

Getting ready to buy stocks once this correction is over? This private sector bank should be on a profit hunter's radar.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

How IL&FS Rating Downgrade Will Impact Your Mutual Funds...(Outside View)

Sep 17, 2018

PersonalFN explains the impact of IL&FS rating downgrade on mutual funds.

How To Identify Sachin Tendulkars And Rahul Dravids Of Tomorrow For Your Mutual Fund Portfolio(Outside View)

Sep 19, 2018

PersonalFN explains how to pick 'undiscovered' or lesser-known mutual funds that are capable of generating big gains for you.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ALEMBIC PHARMA SHARE PRICE


Sep 25, 2018 (Close)

TRACK ALEMBIC PHARMA

  • Track your investment in ALEMBIC PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALEMBIC PHARMA

ALEMBIC PHARMA 5-YR ANALYSIS

COMPARE ALEMBIC PHARMA WITH

MARKET STATS